First quarter (2023-09-01 until 2023-11-30)
● Operating Income amounted to 4,695 (3,012) TSEK, of which
Cellaviva amounted to 4,218 (2,137) TSEK.
● Operating result amounted to -9,796 (-8,918) TSEK.
● Earnings per share* amounted to -0.28 (-0.26) SEK .
● Cash and bank amounted to 40,428 (88,258) TSEK.
● Solidity** amounted to 82.2 (92.7)
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2023/2024: 34,379,523 (34,379,523) shares. Average number of shares for the full year 2022/2023: 34,379,523 (34,379,523847) shares. Number of shares in NextCell as of November 30, 2023: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.
Significant events in the first quarter
●
Significant events after the reporting period
● At the end of January, NextCell published an update on the ongoing clinical trials. The largest ongoing study - ProTrans Young, which includes 66 patients - is progressing well.
This disclosure contains information that
For more information about
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
About
NextCell is a cell therapy company in Phase 2 trials with the drug candidate
https://news.cision.com/nextcell-pharma-ab/r/nextcell-publishes-its-interim-report-1-2023-2024,c3915010
https://mb.cision.com/Main/15834/3915010/2561304.pdf
https://mb.cision.com/Public/15834/3915010/8069a52fa2906132.pdf
(c) 2024 Cision. All rights reserved., source